Persistent LV systolic dysfunction at 6 months or later in MIS-C is the focus of a new meta-analysisHeart Risk After MIS-C: What Lasts Six Months Later

Frontiers in Medicine Published November 5, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Interpret the MIS-C meta-analysis cautiously; the prevalence estimate and limitations are not reported.

This meta-analysis addresses the prevalence of persistent left ventricular systolic dysfunction at 6 months or longer in children and adolescents with MIS-C associated with SARS-CoV-2. The scope is therefore the medium-term cardiac functional outcome after MIS-C, a condition with known acute cardiovascular involvement.

The key finding, the pooled prevalence of persistent LV systolic dysfunction at 6 months or longer, is not reported in the available summary. No effect size, absolute numbers, or statistical measures are provided. Secondary outcomes, safety data, and adverse events are also not reported.

Limitations are not reported by the authors in the available summary, and no certainty assessment or causality note is provided. Funding and conflicts of interest are not reported. The absence of these details limits interpretation of the robustness of any pooled estimate.

Practice relevance is not reported. Clinicians should note that the available summary does not provide a usable prevalence estimate or guidance on follow-up. The findings should be interpreted cautiously pending full publication of the meta-analysis results.

How this fits prior evidence

This meta-analysis on persistent LV systolic dysfunction in MIS-C addresses a gap not covered by prior heart failure items, which focused on orthostatic hypotension prevalence, IV albumin with furosemide for decongestion, nurse-led telemonitoring, exercise effects on inflammatory biomarkers, and PAH-targeted therapy in PH-LHD. None of the prior coverage examined medium-term cardiac function after MIS-C. The current review extends the publication's heart failure coverage to a pediatric post-infectious population, but its key prevalence estimate is not reported in the available summary, so it cannot be directly compared with prior findings.

When a child gets MIS-C, a rare inflammatory reaction that can follow a COVID-19 infection, parents often ask one big question: will their heart be okay? A new review set out to answer part of that. It looked at whether children and teens with MIS-C still had weakened heart pumping, called left ventricular systolic dysfunction, six months or more after their illness.

Here is the honest part. The review does not report a number. It does not tell us how many kids still had heart trouble at that point, or how serious it was. It also does not report how many children were involved, where they were treated, or how the studies were designed.

The review also does not report safety details, side effects, or funding information. And it does not say how certain its conclusions are.

So what does this mean for a parent? It means the question is being asked, but the answer is not in yet. If your child had MIS-C, talk with their doctor about heart follow-up. This review does not give a clear picture of long-term heart risk, and it should not be read as reassurance or as a warning.

What this means for you:

A review asked whether heart weakness lingers six months after MIS-C. It reports no clear answer yet.

Common questions

What is MIS-C?

MIS-C is a rare condition in children and teens that can happen after a SARS-CoV-2 infection. It involves inflammation in the body. This review focused on children and adolescents with MIS-C and looked at heart function, specifically whether the heart's left lower chamber pumps weakly.

Does MIS-C cause lasting heart problems?

That is the exact question this review tried to answer. It looked at whether weakened heart pumping, called left ventricular systolic dysfunction, was still present six months or more after MIS-C. The review does not report a number, so we do not know how common lasting heart weakness is from this work.

How many children were in this review?

The review does not report how many children were involved. It also does not report where they were treated or how the original studies were set up. That missing information makes it hard to know how broadly the findings apply.

Should I worry if my child had MIS-C?

This review does not give a clear answer about long-term heart risk, so it should not be used to reassure or alarm you. If your child had MIS-C, talk with their doctor about heart checkups and what follow-up makes sense for your child.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedNov 2026

View Original Abstract ↓

BackgroundMultisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 frequently involves acute myocardial dysfunction. However, the prevalence of persistent left ventricular (LV) systolic dysfunction at longer-term follow-up remains uncertain. We therefore performed a systematic review and meta-analysis to estimate the prevalence of persistent LV systolic dysfunction at ≥6 months after MIS-C.MethodsWe included observational cohort studies reporting longitudinal echocardiographic follow-up in children and adolescents aged

Persistent LV systolic dysfunction at 6 months or later in MIS-C is the focus of a new meta-analysisHeart Risk After MIS-C: What Lasts Six Months Later

How this fits prior evidence

Common questions

Study Details

Bivalirudin reduces in-hospital major bleeding and 30-day mortality in patients with acute coronary syndrome

Bivalirudin shows lower bleeding risks than heparin for heart patients

Clinical research that matters. Delivered to your inbox.

Persistent LV systolic dysfunction at 6 months or later in MIS-C is the focus of a new meta-analysisHeart Risk After MIS-C: What Lasts Six Months Later

How this fits prior evidence

Common questions

More on Heart Failure

Study Details

Bivalirudin reduces in-hospital major bleeding and 30-day mortality in patients with acute coronary syndrome

Bivalirudin shows lower bleeding risks than heparin for heart patients

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties